|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||1.3600 - 1.3600|
|52-week range||1.3600 - 1.3600|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, a therapeutic vaccine based on the myvac™ technology and powered by NEC’s cutting-edge AI capabilities. In these Phase 1 trials, TG4050 is being administered to patients with head and neck cancer who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. Transgene’s highly innovative myvac™ technology allows the generation of a virus-based immunotherapy within a very short time frame while encoding patient-specific mutations identified and selected by NEC’s Neoantigen Prediction System.